Literature DB >> 31050844

EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus.

Stefan Porubsky1, Birgit Rudolph2, Jens-Carsten Rückert3, Stefan Küffer4, Philipp Ströbel4, Anja C Roden5, Deepali Jain6, Thomas Tousseyn7, Hans Van Veer8, James Huang9, Alberto Antonicelli10, Tseng-Tong Kuo11, Juan Rosai12, Alexander Marx1.   

Abstract

AIMS: In thymic carcinomas, focal clear cell change is a frequent finding. In addition to a prominent, diffuse clear cell morphology, some of these carcinomas show an exuberant hyalinised extracellular matrix, and therefore probably represent a separate entity. However, a characteristic genomic alteration remains elusive. We hypothesised that, analogous to hyalinising clear cell carcinomas of the salivary gland, hyalinising clear cell carcinomas of the thymus might also harbour EWSR1 translocations. METHODS AND
RESULTS: We identified nine archived cases of thymic carcinoma with focal clear cell features and two cases that showed remarkable hyalinised stroma and prominent, diffuse clear cell morphology. These two cases expressed p40 and were negative for Pax8, CD5, and CD117. Programmed death-ligand 1 was highly positive in one case (70%), and negative in the other one. EWSR1 translocation was identified in both cases of hyalinising clear cell carcinoma, and was absent in all nine carcinomas that showed clear cell features without substantial hyalinisation. In one of the EWSR1-translocated cases, a fusion between exon 13 and exon 6 of EWSR1 and ATF1, respectively was identified by next-generation sequencing.
CONCLUSIONS: These findings suggest that the EWSR1 translocation and possibly the EWSR1-ATF1 fusion might be unifying genomic alterations for thymic clear cell carcinomas with prominent hyalinised stroma, for which we propose the term 'hyalinising clear cell carcinoma of the thymus'. Because the immunophenotype is unspecific, testing for the EWSR1 translocation might be helpful in discriminating this entity from other thymic neoplasms or metastases, in particular those with clear cell change.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  ATF1; EWSR1; hyalinising clear cell carcinoma; thymic carcinoma; thymus

Mesh:

Substances:

Year:  2019        PMID: 31050844     DOI: 10.1111/his.13890

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Common and rare carcinomas of the thymus.

Authors:  Anja C Roden; Malgorzata Szolkowska
Journal:  Virchows Arch       Date:  2021-01-03       Impact factor: 4.064

2.  Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.

Authors:  Stefan Porubsky; Peter Jessup; Damien Kee; Rajiv Sharma; Ayame Ochi; Huiling Xu; Jens J Froelich; Louise Nott; Clare Scott; Raef Awad; Cristina Moldovan; Ashutosh A Hardikar; Hanibal Bohnenberger; Stefan Küffer; Philipp Ströbel; Alexander Marx
Journal:  Virchows Arch       Date:  2019-08-10       Impact factor: 4.064

3.  Does Nodal Metastasis and Perineural Invasion Affect Local Control in Hyalinizing Clear Cell Carcinoma of the Oral Cavity? A Case Report with Long Term Follow-Up.

Authors:  John M Le; Darya Gubarev; Yedeh Ying; Anthony Morlandt
Journal:  Head Neck Pathol       Date:  2020-07-27

4.  Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.

Authors:  Weijie Jiang; Tao Wu; Xuan Shi; Jiawen Xu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Screening of Differentially Expressed Iron Death-Related Genes and the Construction of Prognosis Model in Patients with Renal Clear Cell Carcinoma.

Authors:  Ding Wu; Zhenyu Xu; Zhan Shi; Ping Li; Huichen Lv; Jie Huang; Dian Fu
Journal:  Comput Math Methods Med       Date:  2022-08-30       Impact factor: 2.809

6.  EWSR1 rearrangement in papillary thyroid microcarcinoma is related to classic morphology and the presence of small-cell phenotype.

Authors:  Bozidar Kovacevic; Ana Caramelo; Vesna Skuletic; Snezana Cerovic; Catarina Eloy
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.